PLX vs RARE

For growth investors, Ultragenyx Pharmaceutical Inc.

(RARE) is the stronger pick with 20. 1% revenue growth year-over-year, versus -1. 2% for Protalix BioTherapeutics, Inc. (PLX). Analysts rate Protalix BioTherapeutics, Inc. (PLX) a "Buy" — based on 7 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

Over the past 5 years, Protalix BioTherapeutics, Inc.

(PLX) delivered a total return of -36. 5%, compared to -77. 6% for Ultragenyx Pharmaceutical Inc. (RARE). Over 10 years, the gap is even starker: RARE returned -59. 4% versus PLX's -75. 5%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), Protalix BioTherapeutics, Inc.

(PLX) is the lower-risk stock at 1. 38β versus Ultragenyx Pharmaceutical Inc. 's 1. 42β — meaning RARE is approximately 3% more volatile than PLX relative to the S&P 500.

By revenue growth (latest reported year), Ultragenyx Pharmaceutical Inc.

(RARE) is pulling ahead at 20. 1% versus -1. 2% for Protalix BioTherapeutics, Inc. (PLX). On earnings-per-share growth, the picture is similar: Ultragenyx Pharmaceutical Inc. grew EPS 7. 3% year-over-year, compared to -329. 8% for Protalix BioTherapeutics, Inc.. Over a 3-year CAGR, RARE leads at 22. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Protalix BioTherapeutics, Inc.

(PLX) is the more profitable company, earning -12. 5% net margin versus -85. 4% for Ultragenyx Pharmaceutical Inc. — meaning it keeps -12. 5% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PLX leads at -10. 4% versus -79. 5% for RARE. At the gross margin level — before operating expenses — RARE leads at 83. 8%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

None of the stocks in this comparison currently pay a material dividend.

All are effectively zero-yield and should be held for capital appreciation rather than income.

For long-horizon retirement investors, Protalix BioTherapeutics, Inc.

(PLX) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. Both have compounded well over 10 years (PLX: -75. 5%, RARE: -59. 4%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: PLX is a small-cap quality compounder stock; RARE is a small-cap high-growth stock. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.